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ABSTRACT  12 
 13 
The unique character of bile salts to self-assemble into hydrogels in the presence of halide 14 
salts was exploited in this work to facilitate the prediction of human intestinal absorption 15 
(%HIA) for a set of 25 compounds. This was achieved by firstly incorporating each 16 
compound separately within the process of gel formation to create a series of gel-drug 17 
membranes. Scanning Electron Microscopy (SEM) analysis of the freeze-dried samples of the 18 
blank bile salt hydrogels and drug loaded bile salt hydrogels indicated a unique 19 
microstructure made of a network of intertwined fibrils. Drug-loaded sodium deoxycholate 20 
(NaDC) hydrogels were then utilised as the donor phase to study permeability using flow-21 
through and static diffusion cells. The resulting values of the release-permeability coefficient 22 
(Kp) were then analysed, along with other molecular descriptors, for the prediction of human 23 
intestinal absorption (%HIA) using multiple linear regression (MLR). Overall, when 24 
comparing predicted values (using the systems presented in this study) with known literature 25 
values, it can be seen that both methods (i.e. using static and flow through cells) had good 26 
predictability with R2PRED. values of 79.8 % and 79.7 % respectively. This study therefore 27 
proposes a novel, accurate and precise way to predict human intestinal absorption for 28 
compounds of pharmaceutical interest using a simple in vitro permeation system. It is 29 
important to develop alternatives to the current methods used in prediction of HIA which are 30 
expensive and time consuming or include the use of animals. Therefore, the proposed method 31 
in this study being economic and time saving provides superiority over these current methods 32 
and suggests the possibility of its use as an alternate to such methods for prediction of HIA.  33 
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1. Introduction 40 
Due to convenience of the oral route of administration, most of the pharmaceutical 41 
compounds are formulated as orally administered drugs. However, the properties of some 42 
compounds can be incompatible with oral administration. In fact, the pharmaceutical industry 43 
suffers from major financial losses because of the poor bioavailability of some new drugs 44 
after their oral administration, only discovered once in the clinical development stage1-45 
4
.Therefore, poor drug candidates with poor biopharmaceutical properties, such as poor oral 46 
bioavailability, and aqueous solubility should be identified as soon as possible before 47 
entering the clinical development stage in which the cost of research performed for a 48 
compound is significantly high. As a result, there has been a growing interest in the early 49 
prediction of biopharmaceutical properties by means of experimental and theoretical models. 50 
This study provides a rapid and cheap method for the prediction of one of the most important 51 
pharmacokinetic properties of pharmaceutical compounds which is intestinal absorption 52 
through the use of bile salts. The number of recent publications on the physiological 53 
importance of bile salts reflects a growing interest in this area.  It has been found that certain 54 
bile salts, such as sodium deoxycholate (NaDC), are capable of self-assembling into gels 55 
through a process driven by the balance of hydrophobic interactions, hydrogen-bonding, van 56 
der Waals forces and steric effects5-9. The hydrogels made from bile salts are very different 57 
from polymeric gels (which are made from chemical cross-linking) and have specific and 58 
vital roles within the body. Bile salts are a group of cholic acid derivatives, known as 59 
biosurfactants, that have an amphiphilic structure with a steroidal backbone; a distinctive 60 
structure that differentiates this class of surfactants from conventional synthetic surfactants9, 61 
10
. Some important biological functions, such as cholesterol solubilisation, dietary fat and fat 62 
soluble vitamin absorption as well as removal of fatty acids from pancreatic hydrolysis, are 63 
carried out by the aggregates resulting from the self-assembly of bile salts occurring as a 64 
result of their unusual structure9, 11-13. 65 
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Biocompatible fragment containing hydrogels, such as amino acid derivatives14, peptides15, 16, 66 
cholic acid17 derivatives and carbohydrate systems18, 19, have been given notable attention 67 
because of one key benefit, namely their safe use in biomedical applications. The presence of 68 
halide salts has been shown to improve the production of bile salt formed hydrogels20, 21. The 69 
formation of these hydrogels is through a network of intertwined fibrils formed by massive 70 
cycles of bile salt molecules attached together by noncovalent interactions, especially 71 
hydrogen-bonds. It was found that NaCl had a prominent effect on encouraging the gelation 72 
of NaDC solutions to form supramolecular hydrogels with higher gelation capability and 73 
mechanical force because of the small radius of hydration of the NaCl ions20. An important 74 
role is played by both sodium and the chloride ions in the formation of the hydrogels by 75 
reducing the electrostatic repulsion between NaDC polar heads therefore contributing to the 76 
compression of the thickness of the electric double layer20. Furthermore, weak coordination 77 
bonds form between sodium ions and carboxylate groups, stimulating connection of the polar 78 
head of carboxyl groups via hydrogen-bonding which leads to the formation of a more 79 
regular crystalline interface thus shifting the growth of aggregates along one direction 80 
towards fibrous aggregate formation22, 23. In addition, the chloride ions play a role in hydrogel 81 
formation, as well as the weak electrostatic interaction which is thought to exist between the 82 
sodium salt anion (chloride ions) and the α-methylene attached to the carboxylate group of 83 
the bile salt24. NaDC solutions have been reported in literature to give highly viscous gels by 84 
the formation of polymer-like aggregates at pH values less than 7.8 (Figure 1)25, 26. However, 85 
such systems have never been formulated in the presence of pharmaceutical compounds, such 86 
as those considered in this work.  87 
 88 
 89 
Determining human intestinal absorption is a complex, expensive and lengthy process yet is 90 
necessary to understand the behaviour of pharmaceutical compounds in vivo. Developed 91 
systems to predict absorption are highly sought-after and seek to provide a simpler, less 92 
expensive and more ethically acceptable method to predict intestinal absorption. Several 93 
techniques have previously been employed to predict intestinal absorption including cell 94 
culture based models27, such as Caco-2 cells28-35, membrane based models, such as 95 
PAMPA36-39, ex-vivo models, such as Ussing chambers40-42, in situ intestinal perfusion 96 
models43-46 and everted intestinal ring/sac47. Models using spectroscopic48 and 97 
chromatographic49 properties have previously been developed by the authors of this study. 98 
This work however, presents the creation of a novel drug-gel bile salt based product as the 99 
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basis of the analytical donor phase to determine permeation which can ultimately lead to 100 
prediction of intestinal absorption. The synthesised hydrogel was used as a donor phase in 101 
both static diffusion and flow-through cells, with a permeable dialysis membrane for support, 102 
to determine the release-permeability coefficient (Kp) of the studied drugs. This was then 103 
statistically analysed for developing models for prediction of human intestinal absorption.  104 
 105 
2. Experimental 106 
2.1 Chemicals and materials 107 
Sodium deoxycholate (NaDC, 97 %), sodium chloride (NaCl, analytical grade), sodium 108 
dihydrogen orthophosphate dihydrate (NaH2PO4.2H2O, 99 %), disodium hydrogen 109 
orthophosphate anhydrous (Na2HPO4, 99 %) were purchased from Fisher Scientific, 110 
Loughborough, UK. The compounds of pharmaceutical interest considered in this work were: 111 
caffeine 97 % (Sigma Aldrich, Dorset, UK), fenoprofen 97 % (Fluka, Dorset, UK), quinine 112 
96 % (Fluka, Dorset, UK), acetaminophen 99 % (Sigma Aldrich, Dorset, UK), leflunomide 113 
98 % (Sigma Aldrich, Dorset, UK), linezolid >98 % (Sigma Aldrich, Dorset, UK), ketoprofen 114 
98 % (Sigma Aldrich, Dorset, UK), lidocaine 98 % (Sigma Aldrich, Dorset, UK), 115 
indomethacin 99 % (Sigma Aldrich, Dorset, UK), phenylbutazone 99 % (Sigma Aldrich, 116 
Dorset, UK), fluconazole 98 % (Sigma Aldrich, Dorset, UK), carbamazepine 99 % (Sigma 117 
Aldrich, Dorset, UK), cimetidine (Sigma Aldrich, Dorset, UK), moexipril >98 % (Sigma 118 
Aldrich, Dorset, UK), naproxen 98 % (Sigma Aldrich, Dorset, UK), piroxicam 98 % (Sigma 119 
Aldrich, Dorset, UK), zolmitriptan >98 % (Sigma Aldrich, Dorset, UK), haloperidol 99 % 120 
(Sigma Aldrich, Dorset, UK), fosinopril >98 % (Sigma Aldrich, Dorset, UK), ibuprofen 98 % 121 
(BASF, Cheshire, UK), diclofenac 98 % (TCI Europe, Zwijndrecht, Belgium), flurbiprofen 122 
98 % (TCI Europe), gemfibrozil 98 % (TCI Europe), theophylline 98 %, (TCI, Oxford, UK) 123 
and meloxicam 98 % (TCI Europe). Dialysis membrane was a high retention, seamless, 124 
cellulose tubing with an average flat width of 23 mm and molecular weight cut off (MWCO) 125 
of 12400. 126 
2.2 Saturated solubility analysis  127 
Wavelength of maximum absorption (λmax) of each compound was determined by scanning 128 
its solution within (200-400 nm) using UV spectrophotometer. An excess amount of each of 129 
the drugs was added to 5 mL of phosphate buffer (0.2 M disodium orthophosphate, sodium 130 
dihydrogen orthophosphate and sodium chloride at a pH of 7.4) in 7 mL vials, then sealed 131 
and stored at 37 ºC. The solutions were then filtered through 0. 45 µm Nylon filters to 132 
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remove excess solid, diluted by known amounts using buffer, then assayed using UV 133 
spectrophotometry at the pre-determined λmax and compared with  an already established 134 
calibration plot. A calibration plot was established for each compound by preparing a 135 
standard stock solution of each compound, in the previously mentioned buffer/salt mixture at 136 
pH 7.4, from which different volumes were aliquoted out and diluted accordingly for 137 
preparation of different dilutions of the compound. The dilutions were then scanned for 138 
measuring the absorbance and a plot of the compound concentrations against its 139 
corresponding absorbances was then constructed.   140 
2.3 Preparation of bile salt hydrogel with infinite dose of drug  141 
An NaDC-based hydrogel (70 mM) was prepared by gradually adding a specified volume of 142 
phosphate buffer (composition described above). Based on the saturation solubility results, 143 
the infinite dose for each of the drugs under study was calculated where anaccurately 144 
weighed amount of each of the drugs under study was added to an accurately weighed 145 
amount of NaDC (580.4 mg) in a 50 mL beaker for the formation of a 20 mL drug saturated 146 
hydrogel. The mixture of NaDC and drug in buffer was then sonicated in an ultrasonic water 147 
bath for 2 minutes at room temperature until the consistency of the solution thickened and the 148 
gel began to form so the gelation process was visually judged. The gel was left stirring after 149 
sonication and then allowed to stand for 24 hours to ensure homogenous distribution of the 150 
drug throughout the gel.   151 
2.4 Analytical Instrumentation 152 
2.4.1 Diffusion cells 153 
Diffusion cells have been classically considered to be one of the more popular methods used 154 
in prediction of permeation of drugs and chemicals across the skin50, 51. Both static (Franz-155 
type) cells and continuous flow (flow-through) cells were used in this study whereby the 156 
setup of both types of diffusion cells have donor and receptor compartments with a 157 
membrane mounted between and a water jacket to achieve a consistent temperature of 37 oC. 158 
Sink conditions were maintained in both types of cells.  159 
2.4.1.1 Static diffusion cells 160 
A set up of six 30 mL vertical Franz cells, bespoke, were used in the study of the permeation 161 
of drugs from the drug-saturated hydrogels in the donor chamber to buffer in the receptor 162 
chamber per experiment. Each cell was formed of two chambers; donor and receptor 163 
chambers held together by clamps with a dialysis membrane fitted to cover the diffusion area 164 
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(3.14 cm2) mounted between the two chambers as a support for the hydrogel. A 5 mL sample 165 
of the drug-saturated hydrogel was placed in the donor chamber while the clean, dried 166 
receptor chamber was filled with deaerated buffer and allowed to equilibrate at 37 ºC. All 167 
openings, including donor top and receptor arm, were occluded to prevent evaporation. The 168 
receptor compartment was stirred at 450 rpm using a magnetic stirrer. Samples (1 mL) were 169 
extracted at 45 minute intervals over a 6 hour period and analysed using UV 170 
spectrophotometry at the ʎmax of each drug. After each extraction, 1mL of fresh, deaerated 171 
buffer was introduced into the receptor.  172 
2.4.1.2. Flow-through diffusion cells 173 
A set up of six flow through cells were used per experiment (purchased from PermeGear Inc., 174 
Hellertown, PA 18055 USA). Each cell consisted of two compartments; the donor and the 175 
receptor compartments fixed together by clamps and screws with a dialysis membrane cut 176 
down to cover the diffusion area (0.554 cm2) as a support for the hydrogel. 0.8 mL of the 177 
drug saturated hydrogel was placed in the donor chamber while buffer was pumped 178 
continuously through the six receptor compartments at a flow rate of 0.52 mL/min using a 179 
peristaltic pump. All the cells were kept at a temperature of 37 ºC using a heat conducting 180 
cell holder. The donor compartments were covered with moisture-resistant film (Parafilm M, 181 
Alcan packaging) to avoid drying of the hydrogel. Samples from the six cells were collected 182 
in 7 mL vials every 45 minutes over a 6-hour period and analysed using UV 183 
spectrophotometry at the ʎmax of each drug.  184 
All spectrophotometric analysis was undertaken using an Agilent Model Cary 60 UV-Vis 185 
fitted with a Cary single cell Peltier accessory to keep the samples in the sample compartment 186 
at the specified temperature. A quartz cuvette of 10 mm internal thickness was used in all 187 
measurements.  188 
 189 
2.4.2 Scanning Electron Microscopy (SEM) 190 
Electron micrographs of hydrogel with no drug as well as hydrogels saturated with each of 191 
the following drugs (carbamazepine and meloxicam) were obtained using a scanning electron 192 
microscope (Leica Cambridge S360, UK) operating at 15 kV. The hydrogel samples were 193 
freeze dried using (CHRIST ALPHA 2 - 4 LD plus) and mounted on a metal stub with 194 
double-sided adhesive tape and coated under vacuum with gold in an argon atmosphere prior 195 
to observation. Micrographs with different magnifications were taken to facilitate the study of 196 
the morphology of the hydrogels. 197 
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2.4.3 Fourier transform infrared (FT-IR) 198 
The FT-IR spectra (650-4000 cm−1) of hydrogels saturated with (caffeine, carbamazepine, 199 
fluconazole, meloxicam and piroxicam) each of the previously mentioned drugs under study 200 
were air dried then recorded using ATR with a FT-IR spectrophotometer (PerkinElmer, UK). 201 
Spectra with sharp peaks of reasonable intensity were obtained to consider the stability of the 202 
hydrogel after the addition of the drugs. 203 
 204 
2.5 Calculations: 205 
2.5.1 Calculation of permeability coefficient (Kp): 206 
Since the drug was added to the hydrogel in an infinite dose, the permeability coefficient (Kp) 207 
can be calculated from the following relationship 52 : 208 
                                                      Kp = Q /[A .t. (Co  ̶  Ci)]     209 
 210 
Where: 211 
Q: the quantity of drug transported through the hydrogel in time t (min).  212 
Co: the concentration of the drug in the donor chamber (saturated solubility concentration in 213 
the buffer used).  214 
Ci: is the concentration of the drug in the receptor chamber.  215 
A: the area of the exposed hydrogel in cm2.  216 
Since the drug was applied to the hydrogel in an infinite dose, Ci can be simplified to zero. 217 
Kp, defined as the permeant penetration rate per unit concentration, is given in cm/min and 218 
assumed to be a first order process. 219 
2.5.2 Statistical analysis: 220 
Data analysis was conducted using Minitab 17. Multiple linear regression analysis was 221 
conducted where all the molecular descriptors were included and regressed against the 222 
dependant variable %HIA and backward elimination modelling strategy. Variables with high 223 
variance inflation factors (VIF) were removed to take (VIF) to acceptable limits. At the end 224 
an optimum model was obtained that provided a good summary of data. The variables 225 
remaining in the optimal model were assessed for significance and relative importance by 226 
standardised coefficients and the associated p-values. 227 
The predictive ability of the preferred model was assessed using adjusted-R2 and R2 for 228 
prediction (R2PRED) which can indicate the predictive ability of the model itself and 229 
consequently reflects the far wider ability to apply the model. 230 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
3. Results and discussion 231 
3.1 Hydrogel formation and characterisation  232 
The microstructure of the hydrogels formed by NaDC at pH 7.4 was investigated for ‘blank’ 233 
NaDC hydrogel, as well as drug-loaded NaDC hydrogel, using scanning electron microscopy 234 
(SEM). The obtained SEM observations for the blank NaDC hydrogel freeze dried samples 235 
showed a network structure of intertwined fibrils with medium size pockets between (Figure 236 
3). 237 
 238 
Furthermore, the microstructure of the freeze dried samples of two selected drug loaded 239 
hydrogels (carbamazepine and meloxicam) showed the same network structure as the freeze 240 
dried sample of ‘blank’ NaDC hydrogel (Figure 4). 241 
 242 
 243 
The difference in the structure of carbamazepine and meloxicam hydrogels could be 244 
attributed to carbamazepine being more hydrophobic than meloxicam where the log D of 245 
carbamazepine at pH 7.4 is 2.28 53 while that of meloxicam at the same pH is 1.04. As a 246 
result, carbamazepine may have become more involved in the construction of the hydrogel 247 
network thus partially interrupting the crystalline-like arrangement of NaDC molecules 248 
together in the gel.  249 
In contrast, the anionic drug meloxicam is less hydrophobic (log D at pH 7.4=1.04) 53 and has 250 
a comparatively high molecular weight of 351.40 g/mol 53 so is less involved in the main 251 
structure of hydrogel formation. Therefore, in this product the network was more compact 252 
with the presence of the drug entrapped inside the network structure. This was later 253 
confirmed by the higher Kp value obtained for carbamazepine than that obtained for 254 
meloxicam.  255 
FT-IR spectra were obtained upon drying of the sample to confirm the stability of the 256 
hydrogel with the addition of the drugs. These were compared with spectra obtained from the 257 
blank hydrogel samples to identify changes in the characteristic peaks (spectra presented in 258 
Supplementary Information).  259 
It was observed that upon the inclusion of drugs to the NaDC hydrogel there was a decrease 260 
in the wave number of the O-H broad peak appearing at 3334 cm-1 for the blank NaDC 261 
hydrogel sample. This decrease shows destruction of H-bonding between the NaDC 262 
molecules and the formation of new H-bonding between the NaDC and each drug molecule 263 
20
. The decrease was the highest in the case of carbamazepine (3233 cm-1) indicating 264 
carbamazepine was more involved in the hydrogel structure confirming the previous SEM 265 
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results for this drug. In contrast, the decrease was the least in the case of meloxicam (3327 266 
cm-1) showing less inclusion of this drug in the NaDC hydrogel structure thus confirming the 267 
previous SEM results for meloxicam (Figure 4). No appearance of new peaks or 268 
disappearance of existing peaks was observed suggesting no chemical interaction between the 269 
added drugs and NaDC gel. 270 
3.2 Bile salt concentration effects 271 
In this work, a 70 mM NaDC concentration was picked for the preparation of all the drug 272 
loaded hydrogels used in all the permeation studies carried out for the prediction of human 273 
intestinal absorption (HIA). The selection of such value was attributed to the rate of drug 274 
permeation being the highest at this concentration. Such finding was based on testing the 275 
effect of the change in the hydrogel concentration from 50 to 100 mM on the release of 276 
different compounds (neutral, anionic and cationic), as shown in Figure 5. 277 
 278 
According to Figure 5, it can be observed that the permeation rate of anionic drugs 279 
(flurbiprofen, gemfibrozil, ibuprofen and piroxicam) is less affected by the change in the 280 
concentration of NaDC hydrogel than neutral (acetaminophen, carbamazepine and 281 
fluconazole) and cationic (lidocaine) drugs. However, all the selected drugs showed the 282 
highest permeation rate at 70 mM concentration of NaDC. 283 
3.3 Determination of release-permeability 284 
Based on the previous findings, an NaDC concentration of 70 mM was selected to be used in 285 
a permeation study of 25 compounds where the permeation experiment for each compound 286 
was carried out in triplicate. Calculated Kp values were then used in the statistical modelling 287 
of human intestinal absorption. The permeability coefficient (Kp) for twenty-five compounds 288 
was calculated from the slopes of the plots of cumulative amount of drug permeated through 289 
the hydrogel (µg/cm2) against time (min) obtained using both the flow through and static cell 290 
techniques as shown in Figures 6 and 7. The dialysis membrane works only as a support for 291 
the hydrogel to prevent it from falling into the receiver chamber. Since the MWCO of the 292 
used dialysis support is 12400, it will retain compounds of a molecular weight of 12400 or 293 
greater so the studied compounds in solution or in hydrogel are expected to move freely with 294 
the buffer movement from the donor to the receiver chamber without being retained. 295 
Although the hydrogels were prepared in a manner such that the compounds under study 296 
saturated it, these compounds are completely soluble in the hydrogel matrix therefore 297 
allowing the drug molecules to move with the buffer from the gel donor chamber to the 298 
receiver chamber without any hindrance from the dialysis support. For comparison, the 299 
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permeability coefficient was determined for eight selected drugs using only buffer pH 7.4 300 
with no NaDC hydrogel and it was found to be always higher in buffer than in hydrogel 301 
except for acetaminophen which could be attributed to that acetaminophen was the only drug 302 
with significant aqueous solubility, a low molecular weight (151.2 g/mol) 53 and was the least 303 
lipophilic (log Po/w = 0.46) of all the studied drugs 54. 304 
Although the sample volume in the donor chamber when using static cells (5 mL) was higher 305 
than when using flow through cells (0.8 mL), less permeation of the studied compounds was 306 
observed with the static cells than the flow through cells. This could be attributed to the 307 
bigger receptor chamber volume of the static cells used (30 mL) than the flow through cells 308 
(1.5 mL of the receptor phase was collected every 45 min). 309 
 310 
3.4 Statistical modelling of human intestinal absorption (HIA) 311 
For the prediction of human intestinal absorption (HIA), the obtained permeability 312 
coefficients (Kp) from both flow through and static cells were statistically analysed alongside 313 
the reported values of some molecular descriptors such as molecular weight (Mwt), polar 314 
surface area (PSA), freely rotating bonds (FRB), molar volume (VM), dissociation constant 315 
(pKa), aqueous solubility (Sw), number of hydrogen bond donors (nHD) and number of 316 
hydrogen bond acceptors (nHA) against literature values of human intestinal absorption 317 
(HIA) using multiple linear regression. Twenty-five drugs were selected to be used in the 318 
statistical modelling of human intestinal absorption. These drugs are of a wide variety of 319 
physicochemical properties (Mwt, PSA, Sw, RB, nHD, nHA and VM) and having a wide 320 
range of %HIA reported values within (23-100 %) (Tables 1-3).  321 
A linear relationship was found between reported (%HIA) and experimental Kp values but 322 
logit(HIA) was used to improve this relationship as seen in studies of a similar type 55-57. The 323 
human intestinal absorption values were transformed to logit by substitution in the following 324 
equation, where %HIA = %Human Intestinal Absorption. 325 
logit (%HIA) = log (%HIA / (100-%HIA))                 326 
Therefore, all drugs with % HIA values of 100 or 0 % from the training set were removed for 327 
simplification.  328 
Eighteen drugs were used in the development of the final models. Kp, alongside the molecular 329 
descriptors (nHD and VM) were included in the final models of both techniques. 330 
 331 
  332 
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 333 
Modelling of Human intestinal absorption using flow-through cells: 334 
The following model was obtained for the prediction of HIA using flow-through cells: 335 
logit HIA = -0.59 - 0.5522 nHD – 0.006085 VM - 0.765 log Kp 336 
The model’s R2 = 87.58 %, R2adjust.= 84.92 % , R2PRED = 79.80 %, S= 0.267 337 
A 95 % confidence interval for log Kp is given by (-1.19, -0.34). t-statistic and standardised 338 
coefficient of log Kp are -3.86 (p<0.05) and -0.397 respectively suggesting the statistical 339 
significance of log Kp as a predictor. Also the F-ratio of the overall model is statistically 340 
significant, F=32.90 and P value 0.000 (p<0.05). Absence of autocorrelation in the current 341 
regression model was proved by a Durbin- Watson statistic value of 2.532. There was no 342 
marked relationship between residuals and predicted values. Seven compounds 343 
(carbamazepine, fenoprofen, linezolid, naproxen, piroxicam, quinine and zolmitriptan) were 344 
used for testing the obtained model as shown in Table 2. The model was able to successfully 345 
predict the %HIA for six compounds in the test set within a minimum of 0.29 % and a 346 
maximum of 10.97 % difference between the predicted %HIA and the published %HIA. The 347 
model underestimated the %HIA for piroxicam where its predicted value for human intestinal 348 
absorption was found to be 82.65 % against a literature value of 99 % experimentally 349 
obtained in humans. However, the obtained predicted value was found to be closer to a 350 
literature value of 89 % for piroxicam’s intestinal absorption in dogs 71. An overall close 351 
agreement was shown between literature and predicted values of %HIA in Figure 8. 352 
 353 
Prediction of HIA using static cells: 354 
logit HIA = 0.515 - 0.4294 nHD – 0.006005 VM - 0.453 log Kp 355 
The model’s R2 = 86.61 %, R2adjust.= 83.74 % , R2PRED = 79.67 %, S= 0.253 356 
A 95 % confidence interval for log Kp is given by (-0.874, -0.031). t-statistic and 357 
standardised coefficient of log Kp are -2.3 (p<0.05) and -0.261 respectively suggesting the 358 
statistical significance of log Kp as a predictor. Also the F-ratio of the overall model is 359 
statistically significant, F= 30.19 and P value 0.000 (p<0.05). A Durbin- Watson statistic 360 
value of 2.105 proved the absence of autocorrelation in the current regression model. There 361 
was no marked relationship between residuals and predicted values. Seven compounds 362 
(carbamazepine, fenoprofen, indomethacin, linezolid, piroxicam, quinine and zolmitriptan) 363 
were used for testing the obtained model. As shown in Table 3, the model was able to 364 
successfully predict the %HIA for six compounds in the test set within a minimum of 0.6 % 365 
and a maximum of 12.60 % difference between the predicted %HIA and the published 366 
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%HIA. The model underestimated the %HIA for piroxicam where its predicted value for 367 
%HIA was found to be 80.73 % against a literature value of 99 % experimentally obtained in 368 
humans (see reference in Table 2). However, the obtained predicted value was found to be 369 
closer to a literature value of 89 % for piroxicam’s intestinal absorption in dogs 71. The 370 
model’s good predictive power is shown in Figure 9. 371 
The final model equation included permeability coefficient, number of hydrogen bond donors 372 
and molar volume which all correlate well with the absorption values in the human intestine. 373 
Since the permeability coefficient is independent of the donor concentration 82 and it 374 
describes an intrinsic property of the solute to permeate across a specific medium (e.g. 375 
intestine) which is independent of the dose but influenced by the applied vehicle 83. 376 
Therefore, this intrinsic property could be related to one or more of the previously reported 377 
physicochemical properties of the permeating solutes in this study. According to literature, 378 
molar volume (VM) encodes for hydrophobic and dispersion forces while hydrogen bond 379 
acceptor basicity (nHA) accounts for orientation and induction forces84. Both of these 380 
parameters are considered as factors of solute lipophilicity as it can be factorised in to two 381 
sets which are hydrophobicity which accounts for hydrophobic and dispersion forces and also 382 
polar terms which account for hydrogen bonds, orientation and induction forces84. The 383 
mechanisms of drug-biomembrane interactions involve partitioning in to the hydrophobic 384 
core of the membrane which consequently involves the lipophilicity term. Therefore, the 385 
descriptors involved in the final model equation show an important impact in the permeation 386 
process and also confirm the success of such a technique in the simulation of intestinal 387 
membrane for prediction of HIA. However, it should be noted that the majority of the 388 
compounds analysed in this work displayed a comparatively high percentage absorption (as is 389 
often the case for pharmaceutical compounds) and therefore the predictive ability for 390 
compounds with a low absorption should be carefully considered. 391 
 392 
4. Conclusion 393 
Drug-loaded sodium deoxycholate (NaDC) hydrogels were utilised as the donor phase to 394 
study release-permeability using flow-through and static diffusion cells.  Furthermore, 395 
determination of Kp from the permeation of a number of compounds from the prepared NaDC 396 
hydrogels using flow-through cells and static cells was successful in the development of 397 
models of high predictive capabilities for human intestinal absorption by using the 398 
experimentally obtained Kp. Overall, the two permeation methods yielded highly predictive 399 
models of %HIA. Although static cells presented a cheaper option, flow through cells could 400 
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be considered as a better method as it requires smaller volumes of buffer solution and tested 401 
samples in addition to the easier sample collection. NaDC, being a natural physiological 402 
surfactant and having gelation properties in the presence of certain factors, has facilitated the 403 
creation of a simulation of a biological membrane to mimic the absorption process inside the 404 
human intestine which makes it a good alternative for the use of animals in the prediction of 405 
human intestinal absorption of pharmaceutical compounds. At present, the proposed system 406 
may require more drug than ideally desired within early stage development in industry to 407 
complete the analysis yet it does present clear advantages as a novel analytical system. For 408 
example, this technique has the advantage of being a much cheaper alternative to the classical 409 
in vitro cell culture based models (e.g. Caco-2 cells) and membrane based models (e.g. 410 
PAMPA) also it is less time consuming and laboratory intensive.  411 
 412 
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 614 
LEGENDS 615 
Table 1.  A summary of molecular descriptors for the selected twenty-five drugs. 616 
Table 2: Permeability coefficient (log Kp) experimentally obtained from flow-through cells, 617 
predicted %HIA (Pred. %HIA) and experimentally determined literature %HIA (Expt. % 618 
HIA) values for the compounds analysed including seven validation compounds (*). 619 
 620 
Table 3: Permeability coefficient (log Kp) experimentally obtained from static cells, 621 
predicted %HIA (Pred. %HIA) and experimentally determined literature %HIA (Expt. 622 
%HIA) values for the compounds analysed including seven validation compounds (*). 623 
 624 
Fig. 1.  Schematic representation of the formed salt-induced NaDC gels20. 625 
 626 
Fig. 2.  A diagrammatic representation of a static cell (left) and flow through cell 627 
(right) (reference 52). 628 
 629 
Fig. 3. SEM images of gel formed by 70 mM NaDC of magnification power x1000 (left) and 630 
x1300 (right). 631 
Fig. 4. SEM images for a) carbamazepine 70 mM hydrogel and b) meloxicam 70 mM 632 
hydrogel 633 
 634 
Fig. 5. Permeability coefficients (Kp) of eight selected drugs at three different concentrations 635 
of NaDC hydrogels. 636 
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Fig. 6. Plot of cumulative permeated amount of eight selected drugs against time obtained 637 
using flow-through cells. 638 
 639 
Fig. 7. Plot of cumulative permeated amount of eight selected drugs against time obtained 640 
using static cells. 641 
 642 
Fig. 8. Regression plot of predicted %HIA values against literature %HIA. 643 
 644 
Fig. 9. Regression plot of predicted %HIA values against literature %HIA. 645 
 646 
 647 
 648 
 649 
 650 
 651 
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Table 1 
Drug  Mwt 53 pKa 54 Sw 54 HD 53 HA 53 RB 53 VM 53 
Acetaminophen 151.20 9.9 58 14 2 3 1 131.1 
Caffeine  194.20 14 59 21.6 0 6 0 133.4 
Carbamazepine 236.36 13.9 0.21 54, 54, 60 2, 1 54 3 0 186.6 
Cimetidine 252.34 6.8 9.38 3 6 8 198.2 
Diclofenac 296.20 4.15 0.00237 2 3 4 206.8 
Fenoprofen 242.27 4.5 0.033 53 1 3 4 204.7 
Fluconazole 306.27 12.71 9 61 1 7 5 205.3 
Flurbiprofen 244.26 4.42 0.008 1 2 3 203.6 
Fosinopril 563.66 -4.4 0.00101 1 8 15 480.4 
Gemfibrozil 250.33 4.5 62 0.13 63 1 3 6 239.7 
Haloperidol 375.86 8.3 64 0.014 1 3 6 303.3 
Ibuprofen 206.30 5.2 65 0.0684 1 2 4 200.3 
Indomethacin 357.79 4.5 0.000937 1 5 4 269.6 
Ketoprofen 254.30 3.88 0.051 1 3 4 212.2 
Leflunomide 270.21 -0.45 0.021 1 4 3 194.1 
Lidocaine 234.40 7.9 66 0.2337 67 1 3 5 238.8 
Linezolid 337.35 -0.66 1.44 1 7 4 259.0 
Meloxicam 351.40 4.08 0.00715 2 7 2 220.3 
Moexipril 498.57 5.2 0.00585 2 9 12 408.1 
Naproxen 230.26 4.15 0.0159 1 3 3 192.3 
Phenylbutazone 308.37 4.4 68 0.7 62 0 4 5 262.8 
Piroxicam 331.35 6.3 0.023 2 7 2 222.8 
Quinine 324.42 4.2 0.5 1 4 4 266.4 
Theophylline 180.16 8.8 69 22.9 1 6 0 122.9 
Zolmitriptan 287.36 9.52 70 0.19 2 5 5 236.1 
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Table 2 
Drug Expt. %HIA Pred. %HIA Expt. %HIA- Pred. %HIA 
Acetaminophen 8072 84.32 -4.32 
Caffeine  9973 98.87 0.13 
Carbamazepine* 7074 69.71 0.29 
Cimetidine 6072 57.13 2.87 
Diclofenac 8175, 76 88.02 -7.02 
Fenoprofen* 8576 95.97 -10.97 
Fluconazole 9473 92.76 1.24 
Flurbiprofen 9577 93.69 1.31 
Fosinopril 3578 35.68 -0.68 
Gemfibrozil 9575 92.66 2.34 
Haloperidol 6079 49.70 10.3 
Ibuprofen 8575 94.07 -9.07 
Indomethacin 9879 95.38 2.62 
Ketoprofen 9672 93.67 2.33 
Leflunomide 8078 89.14 -9.14 
Lidocaine 9077 88.14 1.86 
Linezolid* 10078 91.16 8.84 
Meloxicam 9072 76.70 13.3 
Moexipril 2378 37.83 -14.83 
Naproxen* 9472 95.06 -1.06 
Phenylbutazone 9673, 79, 80 97.45 -1.45 
Piroxicam* 9980 82.65 16.35 
Quinine* 9577 96.72 -1.72 
Theophylline 9881 98.41 -0.41 
Zolmitriptan* 7071, 78 68.01 1.99 
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Table 3 
Drug Expt. %HIA Pred. %HIA 
Acetaminophen 8072 88.97 
Caffeine  9973 98.24 
Carbamazepine* 7074 70.60 
Cimetidine 6072 57.16 
Diclofenac 8175, 76 85.47 
Fenoprofen* 8576 92.37 
Fluconazole 9473 93.77 
Flurbiprofen 9577 91.79 
Fosinopril 3578 34.68 
Gemfibrozil 9575 90.64 
Haloperidol 6079 62.80 
Ibuprofen 9075, 85 92.01 
Indomethacin* 9879 86.36 
Ketoprofen 9077 89.69 
Leflunomide 8078 86.12 
Lidocaine 8173, 74, 77, 80 86.71 
Linezolid* 10078 87.40 
Meloxicam 9072 77.64 
Moexipril 2378 26.55 
Naproxen 9772, 77 91.95 
Phenylbutazone 9079 94.44 
Piroxicam* 9980 80.73 
Quinine* 9577 93.94 
Theophylline 9685 97.95 
Zolmitriptan* 7071, 78 70.94 
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